China

Mabwell begins first human trial of iron-regulating drug 9MW3011

The study (CTR20230046) is a phase 1, single center, randomized, double-blind,placebo-controlled, ascending dose study to evaluate the safety, ...

 March 15, 2023 | News

Simcere Zaiming partners with Merck for SIM0235 clinical trial in advanced tumors and lymphoma

 Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an in...

 March 15, 2023 | News

Antengene's ATG-022 Phase I CLINCH Trial for Solid Tumor Treatment Receives IND Approval in China

-  Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Assoc...

 March 14, 2023 | News

Everest Medicines' Partner Calliditas Reports Positive Phase 3 Results for Nefecon in IgA Nephropathy Trial

The trial met its primary endpoint with Nefecon demonstrating a highly statistically significant benefit over placebo (p value < 0.0001) in estimated gl...

 March 14, 2023 | News

Boan Biotech Completes Patient Enrollment for Aflibercept Trial in China

Aflibercept is a homodimeric fusion protein consisting of portions of human vascular endothelial growth factor receptor (VEGFR) extracellular domains (VEGF...

 March 13, 2023 | News

Zhongchao Inc. Survey: 80% of Bone Marrow Cancer Patients Satisfied with Services

The survey revealed that approximately 80.6% of patients gave full marks to the patient services provided by Zhongxin Health platform. Zhongxin Health pro...

 March 13, 2023 | News

JW Therapeutics Starts Clinical Trial of Carteyva® for High-Risk Large B-Cell Lymphoma

High-risk large B-cell lymphoma includes large B-cell lymphoma with International Prognostic Index (IPI) score ≥3, and high-grade B-cell lymphoma (HGBL)...

 March 09, 2023 | News

GenScript ProBio Congratulates Eutilex's IND Clearance from MFDS

GenScript ProBio extends congratulations on this. 2 years ago, GenScript ProBio and Eutilex announced that the parties entered into strategic collaboration...

 March 07, 2023 | News

Harbour BioMed's Batoclimab Shows Positive Results in Phase III Trial for Myasthenia Gravis

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel ant...

 March 06, 2023 | News

Porton Advanced and DanausGT Collaborate on Gene and Cell Therapy Development.

As an end-to-end gene and cell therapy service provider, Porton Advanced CDMO offers comprehensive solutions covering plasmids, cell therapy, gene therapy,...

 March 02, 2023 | News

Sanyou Biopharmaceuticals expanding its business outreach to a central hub of biotech network

Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era tow...

 March 02, 2023 | News

Robert Walters China Salary Survey 2023: Easing of Epidemic Control: Recruitment Market Stabilises, Data Security and Compliance Talent being Key Recruitment Targets

The demand for mid-to-senior professionals with specific technical skills and background is increasing, such as new energy, integrated circuits, medical de...

 March 02, 2023 | Analysis

JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma

Primary hepatic cancer is a common malignant tumor of the digestive system worldwide, with high malignancy and hepatic prognosis. As the most common pathol...

 March 01, 2023 | News

Everest Medicines Commences Operations at State-of-the-Art mRNA Vaccine Facility.

 Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercializa...

 February 28, 2023 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close